Table 1.
The demographic, biochemical, immunological, and histological features of PBC patients and control groups.
| Primary Biliary Cholangitis Patients (n = 93) |
Autoimmune Hepatitis Patients (n = 10) |
Primary Sclerosing Cholangitis Patients (n = 25) |
Rheumatoid Arthritis Patients (n = 20) |
Healthy Adult Blood Donors (n = 20) |
|
|---|---|---|---|---|---|
| Age, years | 51 (25–68) | 49 (20–70) | 48 (20–65) | 40 (24–67) | 32 (20–55) |
| Females/males | 89/4 | 8/2 | 11/14 | 20/0 | 15/5 |
| Bilirubin (Total), mg/dL | 2.4 (2.4) | 2.2 (1.9) | 1.5 (2.8) | 0.9 (0.7) | 0.9 (0.3) |
| AST, U/L | 83.9 (51.2) | 43 (73) | 99 (67) | 19 (27) | 24 (24) |
| ALT, U/L | 93.6 (72.5) | 60 (50) | 87 (64) | 26 (38) | 15 (30) |
| AP, U/L | 506.5 (429.2) | 222 (173) | 344 (225) | 44 (28) | 40 (20) |
| γ-GT, U/L | 334.3 (291.9) | 230 (206) | 350 (250) | 54 (59) | 20 (5) |
| AMA or M2 antibody Anti-Sp100 antibody Anti-Sp140 antibody Anti-PML antibody |
76 (82%) 37 (40%) 25 (27%) 29 (31%) |
0 (0%) 0 (0%) 0 (0%) 0 (0%) |
0 (0%) 3 (12%) 1 (4%) 0 (0%) |
0 (0%) 1 (5%) 0 (0%) 0 (0%) |
0 (0%) 0 (0%) 0 (0%) 0 (0%) |
| Early histological stage (I/II) | 52 (56%) | 6 (60%) | 11 (44%) | 0 | 0 |
| Advanced histological stage (III/IV) | 37 (40%) | 3 (30%) | 5 (20%) | 0 | 0 |
| Ambiguous histological stage | 4 (4%) | 0 | 0 | 0 | 0 |
Data are presented as mean (SD). Abbreviations: γ-GT, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; Normal value: bilirubin < 1.2 mg/dL; AST < 40 U/L; ALT < 40 U/L; AP < 115U/mg/dL; γ-GT < 50 U/L; albumin 3.5–5.5 g/dL, γ-globulin < 3 g/dL. Conversion factors to SI units are as follows: for bilirubin, 17.1; for AST, ALT, AP and γ-GT, 0.0167.